JP2023536504A5 - - Google Patents
Info
- Publication number
- JP2023536504A5 JP2023536504A5 JP2023507923A JP2023507923A JP2023536504A5 JP 2023536504 A5 JP2023536504 A5 JP 2023536504A5 JP 2023507923 A JP2023507923 A JP 2023507923A JP 2023507923 A JP2023507923 A JP 2023507923A JP 2023536504 A5 JP2023536504 A5 JP 2023536504A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cancer
- halogen
- tautomer
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026001041A JP2026082834A (ja) | 2020-08-04 | 2026-01-06 | Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202041033326 | 2020-08-04 | ||
| IN202041033326 | 2020-08-04 | ||
| PCT/IB2021/057089 WO2022029617A1 (en) | 2020-08-04 | 2021-08-03 | 6-substituted pyridazine compounds as smarca2 and/or smarca4 degraders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026001041A Division JP2026082834A (ja) | 2020-08-04 | 2026-01-06 | Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023536504A JP2023536504A (ja) | 2023-08-25 |
| JP2023536504A5 true JP2023536504A5 (cg-RX-API-DMAC7.html) | 2024-08-09 |
| JP7857914B2 JP7857914B2 (ja) | 2026-05-13 |
Family
ID=80117730
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507923A Active JP7857914B2 (ja) | 2020-08-04 | 2021-08-03 | Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物 |
| JP2026001041A Pending JP2026082834A (ja) | 2020-08-04 | 2026-01-06 | Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026001041A Pending JP2026082834A (ja) | 2020-08-04 | 2026-01-06 | Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12570650B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4192835A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7857914B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230061349A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116529250A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021320052A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023002089A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3188024A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300387A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023001445A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022029617A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US12624044B2 (en) | 2019-06-10 | 2026-05-12 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2021133917A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| US11679109B2 (en) | 2019-12-23 | 2023-06-20 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| US12606568B2 (en) | 2020-12-09 | 2026-04-21 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| AU2024348074A1 (en) | 2023-09-27 | 2026-04-30 | Haisco Pharmaceutical Group Co., Ltd. | Pyrazole carboxylic acid derivative and use thereof in medicine |
| WO2025196686A1 (en) * | 2024-03-20 | 2025-09-25 | Aurigene Oncology Limited | Fused bicyclic compounds as smarca2 and/or smarca4 degraders |
| CN119874808B (zh) * | 2025-01-02 | 2026-04-17 | 四川大学 | 一种靶向smarca蛋白降解的化合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2952188A1 (en) * | 2014-06-20 | 2015-12-23 | Aurigene Discovery Technologies Limited | Substituted indazole compounds as irak4 inhibitors |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3319944A4 (en) * | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| KR20190140438A (ko) * | 2017-02-28 | 2019-12-19 | 에피자임, 인코포레이티드 | 암 치료를 위한 smarca2의 저해 |
| AU2019249849C1 (en) | 2018-04-01 | 2022-09-29 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| SG11202104495YA (en) * | 2018-04-26 | 2021-05-28 | Aurigene Discovery Tech Ltd | Pyridazine derivatives as smarca2/4 degraders |
| CA3167166A1 (en) * | 2020-01-10 | 2021-07-15 | Amgen Inc. | Smarca2-vhl degraders |
-
2021
- 2021-08-03 MX MX2023001445A patent/MX2023001445A/es unknown
- 2021-08-03 WO PCT/IB2021/057089 patent/WO2022029617A1/en not_active Ceased
- 2021-08-03 JP JP2023507923A patent/JP7857914B2/ja active Active
- 2021-08-03 KR KR1020237005345A patent/KR20230061349A/ko active Pending
- 2021-08-03 US US18/019,721 patent/US12570650B2/en active Active
- 2021-08-03 AU AU2021320052A patent/AU2021320052A1/en active Pending
- 2021-08-03 IL IL300387A patent/IL300387A/en unknown
- 2021-08-03 BR BR112023002089A patent/BR112023002089A2/pt unknown
- 2021-08-03 EP EP21852975.8A patent/EP4192835A4/en active Pending
- 2021-08-03 CA CA3188024A patent/CA3188024A1/en active Pending
- 2021-08-03 CN CN202180068383.4A patent/CN116529250A/zh active Pending
-
2026
- 2026-01-06 JP JP2026001041A patent/JP2026082834A/ja active Pending
- 2026-02-22 US US19/546,365 patent/US20260184705A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021520372A5 (cg-RX-API-DMAC7.html) | ||
| JP2023511471A5 (cg-RX-API-DMAC7.html) | ||
| JP2021519783A5 (cg-RX-API-DMAC7.html) | ||
| RU2468016C2 (ru) | СОЕДИНЕНИЯ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЗАИМОДЕЙСТВИЯ БЕЛКОВ Bcl СО СВЯЗЫВАЮЩИМИ ПАРТНЕРАМИ | |
| CN118791506A (zh) | Kras抑制剂化合物、其药物组合物及其用途 | |
| JP2023511472A5 (cg-RX-API-DMAC7.html) | ||
| RU2016118753A (ru) | Производные пиридилкетона, способ их получения и их фармацевтическое применение | |
| JP2021519308A5 (cg-RX-API-DMAC7.html) | ||
| RU2017118453A (ru) | Производное изоиндолина, промежуточный продукт, способ получения, фармацевтическая композиция и ее применение | |
| JP2012533570A5 (cg-RX-API-DMAC7.html) | ||
| US20130131008A1 (en) | Lipophilic monophosphorylated derivatives and nanoparticles | |
| JP2020515571A5 (cg-RX-API-DMAC7.html) | ||
| WO2018232725A1 (en) | PHARMACEUTICAL COMPOSITIONS | |
| CN109563133A (zh) | 多酰胺化合物及其用途 | |
| JP6871256B2 (ja) | 2−(4−クロロフェニル)−n−((2−(2,6−ジオキソピペリジン−3−イル)−1−オキソイソインドリン−5−イル)メチル)−2,2−ジフルオロアセトアミドの製剤 | |
| KR20140074880A (ko) | 암의 치료를 위한 조성물 및 방법 | |
| JP2021102616A (ja) | 白金耐性の克服における使用のためのテキサフィリン−白金(iv)コンジュゲート及び組成物 | |
| JP4852605B2 (ja) | 放射線治療増強剤 | |
| KR20170118700A (ko) | (1e,4e)-2-아미노-n,n-디프로필-8-(4-(피롤리딘-1-카보닐)페닐)-3h-벤조[b]아제핀-4-카복사미드를 포함하는 고체형, 이의 조성물, 및 이의 용도 | |
| US11883423B2 (en) | Nucleobase analogue derivatives and their applications | |
| JP2023538521A5 (cg-RX-API-DMAC7.html) | ||
| EP4244222B1 (en) | Succinate and crystal form thereof as therapeutics | |
| KR20120015363A (ko) | N-[6-(시스-2,6-디메틸모르폴린-4-일)피리딘-3-일]-2-메틸-4'-(트리플루오로메톡시)[1,1'-비페닐]-3-카르복스아미드의 염 | |
| CA3127502A1 (en) | Formulations comprising heterocyclic protein kinase inhibitors | |
| JP2006503079A (ja) | 抗癌化合物 |